# US 2021/0069322 A1 · Hepatitis b immunisation regimen and compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0069322 A1
- Document ID: US20210069322A1
- Status: Published application
- Kind: A1
- Application number: 16/772,203
- Filed: 2018-12-14
- Published: 2021-03-11
- Earliest claimed: 2017-12-15
- Assignees: Glaxosmithkline Biologicals SA
- Applicants: Glaxosmithkline Biologicals SA
- Inventors: Virginia AMMENDOLA; Babak BAYAT; Clarisse LORIN; Ventzislav Bojidarov VASSILEV; Alessandra VITELLI
- Web page: https://patentgrep.com/patent/US20210069322A1

## CPC

- A61K 39/292: {Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen}
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 39/12: Viral antigens
- A61K 39/29: Hepatitis virus
- A61P 31/20: for DNA viruses
- C07K 14/02: Hepadnaviridae, e.g. hepatitis B virus
- C12N 15/86: Viral vectors
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C12N 2710/10341: Use of virus, viral particle or viral elements as a vector
- C12N 2710/10343: viral genome or elements thereof as genetic vector
- C12N 2710/24141: Use of virus, viral particle or viral elements as a vector
- C12N 2710/24143: viral genome or elements thereof as genetic vector
- C12N 2730/00071: Demonstrated in vivo effect
- C12N 2730/10134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

There is provided a method of treating chronic hepatitis B infection (CHB) in a human, comprising the steps of: a) administering to the human a composition comprising a replication-defective chimpanzee adenoviral (ChAd) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B virus core antigen (HBc); b) administering to the human a composition comprising a Modified Vaccinia Virus Ankara (MVA) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B virus core antigen (HBc); and c) administering to the human a composition comprising a recombinant hepatitis B surface antigen (HBs), recombinant hepatitis B virus core antigen (HBc) and an adjuvant.

## Claims

### Claim 1

A method of treating chronic hepatitis B infection (CHB) in a human, comprising the steps of:
a) administering to the human a composition comprising a replication-defective chimpanzee adenoviral (ChAd) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B virus core antigen (HBc);
b) administering to the human a composition comprising a Modified Vaccinia Virus Ankara (MVA) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B virus core antigen (HBc); and
c) administering to the human a composition comprising a recombinant hepatitis B surface antigen (HBs), a recombinant hepatitis B virus core antigen (HBc) and an adjuvant.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the steps of the method are carried out sequentially, with step a) preceding step b) and step b) preceding step c).

### Claim 3 (depends on 2)

The method according to claim 2, wherein step c) of the method is repeated.

### Claim 4 (depends on 1, 2, 3)

The method according to claim 1, claim 2 or claim 3 in which the period of time between each step is 1 week, 2 weeks, 4 weeks, 6 weeks 8 weeks, 12 weeks, 6 months or 12 months, for example 4 weeks or 8 weeks.

### Claim 5 (depends on 1)

The method according to claim 1, wherein step c) is carried out concomitantly with step a) and/or with step b).

### Claim 6

A method of treating chronic hepatitis B infection (CHB) in a human, comprising the steps of:
a) administering to the human i) a composition comprising a replication-defective chimpanzee adenoviral (ChAd) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B virus core antigen (HBc) and, concomitantly, ii) a composition comprising a recombinant hepatitis B surface antigen (HBs), a recombinant hepatitis B virus core antigen (HBc) and an adjuvant; and
b) administering to the human i) a composition comprising a Modified Vaccinia Virus Ankara (MVA) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B virus core antigen (HBc) and, concomitantly, a composition comprising a recombinant hepatitis B surface antigen (HBs), are combinant hepatitis B virus core antigen (HBc) and an adjuvant.

### Claim 7

A method of treating chronic hepatitis B infection (CHB) in a human with an immunogenic composition, the immunogenic combination comprising:
a) a composition comprising a replication-defective chimpanzee adenoviral (ChAd) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B virus core antigen (HBc);
b) a composition comprising a Modified Vaccinia Virus Ankara (MVA) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B virus core antigen (HBc); and
a composition comprising a recombinant hepatitis B surface antigen (HBs), recombinant hepatitis B virus core antigen (HBc) and an adjuvant
wherein method comprises administering the compositions sequentially or concomitantly to the human.

### Claim 8

A method of treating chronic hepatitis B infection (CHB) in a human with an immunogenic composition, the immunogenic composition comprising a replication-defective chimpanzee adenoviral (ChAd) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs), a nucleic acid encoding a hepatitis B virus core antigen (HBc) and a nucleic acid encoding the human invariant chain (hIi) fused to the HBc, wherein the method comprises administering the composition in a prime-boost regimen with at least one other immunogenic composition.

### Claim 9 (depends on 7)

The method according to claim 7, wherein the immunogenic composition further comprises one or more recombinant HBV protein antigens.

### Claim 10

A method of treating or preventing chronic hepatitis B infection in a human with an immunogenic composition, where the immunogenic composition comprises a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B virus core antigen (HBc)-wherein the method comprises administering the immunogenic composition in a prime-boost regimen with at least one other immunogenic composition.

### Claim 11 (depends on 10)

The method according to claim 10, wherein the immunogenic composition further comprises one or more recombinant HBV protein antigens.

### Claim 12

A method of treating chronic hepatitis B infection (CHB) in a human with an immunogenic composition, the immunogenic composition comprising a recombinant hepatitis B surface antigen (HBs), a C-terminal truncated recombinant hepatitis B virus core antigen (HBc) and an adjuvant containing MPL and QS-21, wherein the method comprises administering the composition in a prime-boost regimen with at least one other immunogenic composition.

### Claim 13 (depends on 12)

The method according to claim 12 in which the ratio of HBc to HBs in the immunogenic composition is greater than 1.

### Claim 14 (depends on 13)

The method according to claim 13 in which the ratio of HBc to HBs in the immunogenic composition is 4:1.

### Claim 15 (depends on 12)

The method according to claim 12 wherein the immunogenic composition further comprises one or more vectors encoding one or more HBV protein antigens.

### Claim 16

(canceled)

### Claim 17

(canceled)

### Claim 18

(canceled)
